AIM: To investigate the relationship between the gutliver axis and nonalcoholic fatty liver
disease (NAFLD), we performed a meta-analysis to evaluate the effects of probiotic therapy …

Background and aim Considering the increasing prevalence of non-alcoholic steatohepatitis
(NASH) and treatment gaps, this study aimed to evaluate the effect of probiotic …

Methods: Patients with NAFLD were randomised to 10-14 months intervention with either
synbiotic (fructooligosaccharides; 4 g/day+ Bifidobacterium animalis subsp. lactis BB-12)(n …

We read with great interest the review article written by Bibbò et al.[1] entitled “Gut
Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease,” in which the …

Background & aims Non-alcoholic fatty liver disease (NAFLD) is a common, multifactorial
liver disease with rapidly increasing prevalence. During the past decade, several lines of …

Advances have been made in the field of nonalcoholic fatty liver disease in 2019. One paper
highlights the role of gut microbiota in hepatocellular carcinoma (HCC) pathogenesis …

It is now well established that gut flora and chronic liver diseases are closely interrelated.
This association is most evident at late stages of the disease: cirrhosis and impaired liver …

The interaction of gut microbiota, related metabolites and inflammation factors with
nonalcoholic fatty liver disease (NAFLD) remains unclearly defined. The aim of this …

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder in the world, yet
the pathogenesis of the disease is not well elucidated. Due to the close anatomic and …

There is a need to introduce standardized treatment options for non-alcoholic fatty liver
disease (NAFLD) due to its global prevalence and the complications of this disease. Many …